Abstract
Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of 10B (45-74ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of l-BPA-fructose complex (500mg BPA/kg).
| Original language | English |
|---|---|
| Pages (from-to) | 1721-1724 |
| Number of pages | 4 |
| Journal | Applied Radiation and Isotopes |
| Volume | 69 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 12-2011 |
| Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Radiation
Fingerprint
Dive into the research topics of 'Boron neutron capture therapy for clear cell sarcoma (CCS): Biodistribution study of p-borono-l-phenylalanine in CCS-bearing animal models'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver